This community-based cross-sectional study assessed mpox seroprevalence and potential undocumented exposures in the Canadian provinces of Manitoba and Alberta. The work was conducted to estimate gaps in surveillance and population-level immunity after the 2022 global mpox outbreak, when cases among gay, bisexual and other men who have sex with men (gbMSM) were disproportionately reported. The authors note that stigma and changing epidemiology may have reduced health-seeking behaviour and contributed to misdiagnosis early in the outbreak. Serologic testing was used as a tool to identify prior Orthopoxvirus exposures that were not captured by case counts.
Between June 2024 and December 2025, the investigators enrolled 275 individuals from Manitoba and Alberta who identified as potentially eligible for provincial mpox vaccination. Eligibility criteria reflected provincial vaccination guidance and included, but were not limited to, gbMSM, gender-diverse individuals, and sex workers. Recruitment aimed to capture people who would have been eligible under local programs rather than a population-representative sample of the general public.
Participants provided dried blood spot specimens. These samples were analyzed with the Meso Scale Discovery Orthopoxvirus assay. The assay targeted five orthologous mpox and vaccinia virus antigens to detect seroreactivity indicative of prior Orthopoxvirus exposure or vaccination. The authors reported self-reported vaccination status alongside serologic findings to distinguish vaccine-induced from infection-associated seroreactivity where possible.
Among the 275 participants, 14.5% self-reported having received the mpox vaccine. Among those who did not report prior Orthopoxvirus vaccination, 5.9% were seroreactive to multiple mpox antigens. The presence of multi-antigen seroreactivity in participants without reported vaccination is interpreted by the authors as evidence consistent with undetected mpox circulation in Manitoba and Alberta.
The study also observed that seroreactivity was not confined to the groups prioritized by vaccination guidance. While vaccine eligibility principally targeted men who have sex with men, the set of participants classified as seroreactive included an expanded range of gender identities and sexual orientation categories. The authors highlight this mismatch between seroreactivity distribution and vaccine eligibility criteria as an important observation.
The investigators conclude that the detection of seroreactivity among individuals who did not report vaccination suggests there were undocumented mpox exposures in the two provinces during the study period. Because seroreactivity spanned diverse gender and sexual orientation identities, the authors argue that narrower vaccine eligibility policies focused on specific gender or sexuality categories may have missed people at risk.
On this basis, the study supports consideration of broader mpox vaccine eligibility that is not restricted by gender or sexuality labels, to better encompass populations who may be exposed. The authors propose that expanding eligibility criteria could improve coverage of at-risk individuals and reduce gaps in surveillance-driven prevention efforts.
Ethical approvals were obtained from the Committee for Harmonized Health Impact, Privacy, and Ethics Review Health Research Ethics Board at the University of Manitoba (IRB00012696) and the University of Alberta (Pro00146978). All participants provided informed, written consent. The authors declared no competing interests. Data are available upon reasonable request from the study authors.
Funding was reported from the Canadian Institutes of Health Research and the International Development Research Centre. The preprint was posted on medRxiv; the DOI is reported in the source. Specific trial registration details and any additional protocol elements were stated to be in accordance with institutional policies as reported by the authors.
The source article describes the study design, assay approach, seroprevalence and the mismatch between seroreactivity and vaccination eligibility. The preprint text did not provide additional granular details in the abstract about sampling frame representativeness, confidence intervals for estimates, demographic breakdowns in full, or the exact antigen-specific assay thresholds; those details were not reported in the abstract section of the source and therefore are not reproduced here.
Serologic screening using multi-antigen Orthopoxvirus assays can reveal undocumented exposures that are not captured by routine surveillance. In contexts where vaccine eligibility was narrowly defined, serologic evidence of exposure across diverse gender and sexuality groups suggests revisiting eligibility criteria to better identify and protect those at risk.